Mayne Pharma Group Ltd
Buy, Hold or Sell?
Let's analyse Mayne Pharma Group Ltd together
I guess you are interested in Mayne Pharma Group Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
I'm going to help you getting a better view of Mayne Pharma Group Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
You can find me behind Let's Analyse Together in the top-right of each section.
Get notifications about Mayne Pharma Group Ltd
I send you an email if I find something interesting about Mayne Pharma Group Ltd.
Quick analysis of Mayne Pharma Group Ltd (30 sec.)
1. Valuation of Mayne Pharma Group Ltd (5 min.)
A$3.79
A$6.55
2. Growth of Mayne Pharma Group Ltd (5 min.)
Is Mayne Pharma Group Ltd growing?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
How rich? | $367.8m | $509.3m | -$141.5m | -38.5% |
How much money is Mayne Pharma Group Ltd making?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
Making money | -$180.8m | -$138m | -$42.8m | ? |
Net Profit Margin | -64.6% | -52.2% | - | - |
How much money comes from the company's main activities?
3. Financial Health of Mayne Pharma Group Ltd (5 min.)
4. Comparing to competitors in the Drug Manufacturers-General industry (5 min.)
Industry Rankings (Drug Manufacturers-General)
Fundamentals of Mayne Pharma Group Ltd
Financial Health
Compared to previous year | Compared to industry | |
---|---|---|
The company is making a huge loss. | ||
Using its assets, the company is very inefficient in making profit. | ||
Using its investors money, the company is very inefficient in making profit. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is operating less efficient. | ||
The company is inefficient in keeping operating costs low. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is just not able to pay all its short-term debts. | ||
The company is just not able to pay all its short-term debts with the most liquid assets. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is able to pay all its debts by selling its assets. | ||
The company is able to pay all its debts with equity. |
1.1. Profitability of Mayne Pharma Group Ltd.
1.1. Profitability
1.1.1. Net Profit Margin
- Above 10% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
- A Net Profit Margin of -64.6% means that $-0.65 for each $1 in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of Mayne Pharma Group Ltd:
Trends
- The YOY is -52.2%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -43.4%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -17.0%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -64.6% | TTM | -64.6% | 0.0% | |
TTM | -64.6% | YOY | -52.2% | -12.4% | |
TTM | -64.6% | 5Y | -43.4% | -21.2% | |
5Y | -43.4% | 10Y | -17.0% | -26.4% |
Compared to industry (Drug Manufacturers-General)
Let compare the company's Net Profit Margin with the average (mean) in the Drug Manufacturers-General industry:
- The MRQ average (mean) in the Drug Manufacturers-General industry is 15.7%. trending down. -2
- The TTM average (mean) in the Drug Manufacturers-General industry is 14.8%. trending down. -2
1.1.2. Return on Assets
- Above 5% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
- -21.3% Return on Assets means that Mayne Pharma Group Ltd generated $-0.21 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of Mayne Pharma Group Ltd:
Trends
- The YOY is -14.3%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -13.1%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -5.0%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -21.3% | TTM | -21.3% | 0.0% | |
TTM | -21.3% | YOY | -14.3% | -7.0% | |
TTM | -21.3% | 5Y | -13.1% | -8.2% | |
5Y | -13.1% | 10Y | -5.0% | -8.1% |
Compared to industry (Drug Manufacturers-General)
Let compare the company's Return on Assets with the average (mean) in the Drug Manufacturers-General industry:
- The MRQ average (mean) in the Drug Manufacturers-General industry is 2.5%. trending down. -2
- The TTM average (mean) in the Drug Manufacturers-General industry is 2.8%. trending down. -2
1.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
- -48.5% Return on Equity means Mayne Pharma Group Ltd generated $-0.49 for each $1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of Mayne Pharma Group Ltd:
Trends
- The YOY is -27.2%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -24.8%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -9.3%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -48.5% | TTM | -48.5% | 0.0% | |
TTM | -48.5% | YOY | -27.2% | -21.3% | |
TTM | -48.5% | 5Y | -24.8% | -23.7% | |
5Y | -24.8% | 10Y | -9.3% | -15.4% |
Compared to industry (Drug Manufacturers-General)
Let compare the company's Return on Equity with the average (mean) in the Drug Manufacturers-General industry:
- The MRQ average (mean) in the Drug Manufacturers-General industry is 5.2%. trending down. -2
- The TTM average (mean) in the Drug Manufacturers-General industry is 6.6%. trending down. -2
1.2. Operating Efficiency of Mayne Pharma Group Ltd.
1.2. Operating Efficiency
1.2.1. Operating Margin
- Measures how much profit Mayne Pharma Group Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
- An Operating Margin of 2.7% means the company generated $0.03 for each $1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of Mayne Pharma Group Ltd:
Trends
- The YOY is 1.8%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is -4.0%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is 6.1%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 2.7% | TTM | 2.7% | 0.0% | |
TTM | 2.7% | YOY | 1.8% | +0.9% | |
TTM | 2.7% | 5Y | -4.0% | +6.7% | |
5Y | -4.0% | 10Y | 6.1% | -10.1% |
Compared to industry (Drug Manufacturers-General)
Let compare the company's Operating Margin with the average (mean) in the Drug Manufacturers-General industry:
- The MRQ average (mean) in the Drug Manufacturers-General industry is 22.0%. trending down. -2
- The TTM average (mean) in the Drug Manufacturers-General industry is 17.2%. trending down. -2
1.2.2. Operating Ratio
- Below 1 is considered healthy (always compare to Drug Manufacturers-General industry mean).
- An Operation Ratio of 1.00 means that the operating costs are $1.00 for each $1 in net sales.
Let's take a look of the Operating Ratio trends of Mayne Pharma Group Ltd:
Trends
- The YOY is 0.947. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.969. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.916. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 1.004 | TTM | 1.004 | 0.000 | |
TTM | 1.004 | YOY | 0.947 | +0.057 | |
TTM | 1.004 | 5Y | 0.969 | +0.035 | |
5Y | 0.969 | 10Y | 0.916 | +0.052 |
Compared to industry (Drug Manufacturers-General)
Let compare the company's Operating Ratio with the average (mean) in the Drug Manufacturers-General industry:
- The MRQ average (mean) in the Drug Manufacturers-General industry is 0.965. trending up. -2
- The TTM average (mean) in the Drug Manufacturers-General industry is 0.963. trending up. -2
1.3. Liquidity of Mayne Pharma Group Ltd.
1.3. Liquidity
1.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare to Drug Manufacturers-General industry mean).
- A Current Ratio of 0.84 means the company has $0.84 in assets for each $1 in short-term debts.
Let's take a look of the Current Ratio trends of Mayne Pharma Group Ltd:
Trends
- The YOY is 1.872. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 1.971. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 1.834. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.838 | TTM | 0.838 | 0.000 | |
TTM | 0.838 | YOY | 1.872 | -1.034 | |
TTM | 0.838 | 5Y | 1.971 | -1.133 | |
5Y | 1.971 | 10Y | 1.834 | +0.137 |
Compared to industry (Drug Manufacturers-General)
Let compare the company's Current Ratio with the average (mean) in the Drug Manufacturers-General industry:
- The MRQ average (mean) in the Drug Manufacturers-General industry is 1.645. trending down. -2
- The TTM average (mean) in the Drug Manufacturers-General industry is 1.574. trending down. -2
1.3.2. Quick Ratio
- Above 1 is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
- A Quick Ratio of 0.60 means the company can pay off $0.60 for each $1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of Mayne Pharma Group Ltd:
Trends
- The YOY is 1.264. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 1.397. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 1.271. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.598 | TTM | 0.598 | 0.000 | |
TTM | 0.598 | YOY | 1.264 | -0.666 | |
TTM | 0.598 | 5Y | 1.397 | -0.800 | |
5Y | 1.397 | 10Y | 1.271 | +0.126 |
Compared to industry (Drug Manufacturers-General)
Let compare the company's Quick Ratio with the average (mean) in the Drug Manufacturers-General industry:
- The MRQ average (mean) in the Drug Manufacturers-General industry is 0.833. trending down. -2
- The TTM average (mean) in the Drug Manufacturers-General industry is 0.916. trending down. -2
1.4. Solvency of Mayne Pharma Group Ltd.
1.3. Liquidity
1.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compare Mayne Pharma Group Ltd to Drug Manufacturers-General industry mean.
- A Debt to Asset Ratio of 0.57 means that Mayne Pharma Group Ltd assets are financed with 56.7% credit (debt) and the remaining percentage (100% - 56.7%) is financed by its owners/shareholders.
Let's take a look of the Debt to Asset Ratio trends of Mayne Pharma Group Ltd:
Trends
- The YOY is 0.473. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.435. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.452. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.567 | TTM | 0.567 | 0.000 | |
TTM | 0.567 | YOY | 0.473 | +0.095 | |
TTM | 0.567 | 5Y | 0.435 | +0.133 | |
5Y | 0.435 | 10Y | 0.452 | -0.017 |
Compared to industry (Drug Manufacturers-General)
Let compare the company's Debt to Asset Ratio with the average (mean) in the Drug Manufacturers-General industry:
- The MRQ average (mean) in the Drug Manufacturers-General industry is 0.514. trending up. -2
- The TTM average (mean) in the Drug Manufacturers-General industry is 0.501. trending up. -2
1.4.2. Debt to Equity Ratio
- Below 2 is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
- A Debt to Equity ratio of 129.4% means that company has $1.29 debt for each $1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of Mayne Pharma Group Ltd:
Trends
- The YOY is 0.900. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.810. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 1.003. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 1.294 | TTM | 1.294 | 0.000 | |
TTM | 1.294 | YOY | 0.900 | +0.394 | |
TTM | 1.294 | 5Y | 0.810 | +0.484 | |
5Y | 0.810 | 10Y | 1.003 | -0.192 |
Compared to industry (Drug Manufacturers-General)
Let compare the company's Debt to Equity Ratio with the average (mean) in the Drug Manufacturers-General industry:
- The MRQ average (mean) in the Drug Manufacturers-General industry is 1.059. trending up. -2
- The TTM average (mean) in the Drug Manufacturers-General industry is 1.008. trending up. -2
2. Market Valuation of Mayne Pharma Group Ltd
2. Earnings Per Share
2.1. Price to Earnings Ratio
- Above 15 is considered overpriced but always compare Mayne Pharma Group Ltd to the Drug Manufacturers-General industry mean.
- A PE ratio of -0.08 means the investor is paying $-0.08 for every $1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of Mayne Pharma Group Ltd:
Trends
- The YOY is -2.413. Compared to the TTM, the mid term is trending up. -2
- The 5Y is -4.207. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 8.595. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -1.224 | MRQ | -0.081 | -1.144 | |
MRQ | -0.081 | TTM | -0.081 | 0.000 | |
TTM | -0.081 | YOY | -2.413 | +2.332 | |
TTM | -0.081 | 5Y | -4.207 | +4.126 | |
5Y | -4.207 | 10Y | 8.595 | -12.802 |
Compared to industry (Drug Manufacturers-General)
Let compare the company's Price to Earnings Ratio with the average (mean) in the Drug Manufacturers-General industry:
- The MRQ average (mean) in the Drug Manufacturers-General industry is 45.468. trending down. +2
- The TTM average (mean) in the Drug Manufacturers-General industry is 40.569. trending down. +2
2.2. Price Earnings to Growth Ratio
- Lower is better.
- A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.
Let's take a look of the Price Earnings to Growth Ratio trends of Mayne Pharma Group Ltd:
Trends
- The YOY is 12.968. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 11.189. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 61.731. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.004 | TTM | 0.004 | 0.000 | |
TTM | 0.004 | YOY | 12.968 | -12.964 | |
TTM | 0.004 | 5Y | 11.189 | -11.185 | |
5Y | 11.189 | 10Y | 61.731 | -50.542 |
Compared to industry (Drug Manufacturers-General)
Let compare the company's Price Earnings to Growth Ratio with the average (mean) in the Drug Manufacturers-General industry:
- The MRQ average (mean) in the Drug Manufacturers-General industry is 40.731. trending down. +2
- The TTM average (mean) in the Drug Manufacturers-General industry is 73.479. trending down. +2
2. Book Value per Share
2.3. Price to Book Ratio
- At or below 1 is considered healthy (always compare to Drug Manufacturers-General industry mean).
- A PB ratio of 0.04 means the investor is paying $0.04 for each $1 in book value.
Let's take a look of the Price to Book Ratio trends of Mayne Pharma Group Ltd:
Trends
- The YOY is 0.652. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 0.605. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 1.499. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | 0.579 | MRQ | 0.038 | +0.541 | |
MRQ | 0.038 | TTM | 0.038 | 0.000 | |
TTM | 0.038 | YOY | 0.652 | -0.614 | |
TTM | 0.038 | 5Y | 0.605 | -0.567 | |
5Y | 0.605 | 10Y | 1.499 | -0.894 |
Compared to industry (Drug Manufacturers-General)
Let compare the company's Price to Book Ratio with the average (mean) in the Drug Manufacturers-General industry:
- The MRQ average (mean) in the Drug Manufacturers-General industry is 3.827. trending down. +2
- The TTM average (mean) in the Drug Manufacturers-General industry is 3.943. trending down. +2
2. Total Gains per Share
3. Holders & Insider Transactions
Let's take a look at which institutions, funds and insiders are holding shares of Mayne Pharma Group Ltd.
3.1. Funds holding Mayne Pharma Group Ltd
Date | Name | Total Shares | Total Assets | Current Shares | Change | % |
---|---|---|---|---|---|---|
2021-01-31 | DFA International Small Cap Value Portfolio | 1.37 | - | 23019372 | - | - |
2020-10-31 | Vanguard International Stock Index-Total Intl Stock Indx | 1.3300001 | - | 22380066 | - | - |
2020-12-31 | Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 0.63 | - | 10521396 | - | - |
2021-01-31 | DFA Asia Pacific Small Company Series | 0.57 | - | 9518774 | - | - |
2021-02-28 | iShares MSCI EAFE Small Cap ETF | 0.39 | - | 6505249 | - | - |
2020-10-31 | Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 0.26 | - | 4447060 | - | - |
2021-01-31 | DFA International Core Equity Portfolio | 0.23 | - | 3936421 | - | - |
2020-12-31 | College Retirement Equities Fund-Stock Account | 0.22 | - | 3621766 | - | - |
2020-11-30 | Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 0.14 | - | 2330522 | - | - |
2021-01-31 | TIAA-CREF Funds-Quant International Small Cap Equity Fund | 0.14 | - | 2299815 | - | - |
Total | 5.2800001 | 0 | 88580441 | 0 | 0.0% |
4. Summary
4.1. Key Performance Indicators
The key performance indicators of Mayne Pharma Group Ltd compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | 6.058 | 6.058 | 0% | -0.191 | +103% | 1.130 | +436% | 0.641 | +846% |
Book Value Growth | - | - | 0.722 | 0.722 | 0% | 0.740 | -2% | 0.850 | -15% | 1.620 | -55% |
Book Value Per Share | - | - | 6.549 | 6.549 | 0% | 0.491 | +1234% | 1.851 | +254% | 1.159 | +465% |
Book Value Per Share Growth | - | - | 13.338 | 13.338 | 0% | 0.720 | +1751% | 3.361 | +297% | 2.441 | +447% |
Current Ratio | - | - | 0.838 | 0.838 | 0% | 1.872 | -55% | 1.971 | -57% | 1.834 | -54% |
Debt To Asset Ratio | - | - | 0.567 | 0.567 | 0% | 0.473 | +20% | 0.435 | +30% | 0.452 | +26% |
Debt To Equity Ratio | - | - | 1.294 | 1.294 | 0% | 0.900 | +44% | 0.810 | +60% | 1.003 | +29% |
Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Eps | - | - | -3.095 | -3.095 | 0% | -0.133 | -96% | -0.714 | -77% | -0.343 | -89% |
Eps Growth | - | - | -21.340 | -21.340 | 0% | -0.186 | -99% | -4.285 | -80% | -0.863 | -96% |
Free Cash Flow Per Share | - | - | -0.139 | -0.139 | 0% | -0.016 | -89% | -0.045 | -68% | -0.112 | -20% |
Free Cash Flow Per Share Growth | - | - | -6.724 | -6.724 | 0% | 1.482 | -554% | -0.953 | -86% | -6.908 | +3% |
Free Cash Flow To Equity Per Share | - | - | 0.185 | 0.185 | 0% | -0.042 | +123% | 0.016 | +1031% | 0.046 | +302% |
Free Cash Flow To Equity Per Share Growth | - | - | 6.439 | 6.439 | 0% | 0.503 | +1181% | 1.606 | +301% | 2.109 | +205% |
Gross Profit Margin | - | - | 1.382 | 1.382 | 0% | 1.272 | +9% | 1.433 | -4% | 0.973 | +42% |
Intrinsic Value_10Y_max | - | - | 12.053 | - | - | - | - | - | - | - | - |
Intrinsic Value_10Y_min | - | - | 0.240 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_max | - | - | 0.212 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_min | - | - | -0.078 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_max | - | - | 1.396 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_min | - | - | -0.148 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_max | - | - | 3.495 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_min | - | - | -0.122 | - | - | - | - | - | - | - | - |
Net Profit Margin | - | - | -0.646 | -0.646 | 0% | -0.522 | -19% | -0.434 | -33% | -0.170 | -74% |
Operating Margin | - | - | 0.027 | 0.027 | 0% | 0.018 | +47% | -0.040 | +250% | 0.061 | -56% |
Operating Ratio | - | - | 1.004 | 1.004 | 0% | 0.947 | +6% | 0.969 | +4% | 0.916 | +10% |
Pb Ratio | 0.579 | +93% | 0.038 | 0.038 | 0% | 0.652 | -94% | 0.605 | -94% | 1.499 | -97% |
Pe Ratio | -1.224 | -1416% | -0.081 | -0.081 | 0% | -2.413 | +2887% | -4.207 | +5108% | 8.595 | -101% |
Peg Ratio | - | - | 0.004 | 0.004 | 0% | 12.968 | -100% | 11.189 | -100% | 61.731 | -100% |
Price Per Share | 3.790 | +93% | 0.250 | 0.250 | 0% | 0.320 | -22% | 0.467 | -46% | 0.744 | -66% |
Price To Total Gains Ratio | 0.626 | +93% | 0.041 | 0.041 | 0% | -1.680 | +4170% | -17.147 | +41648% | 5.389 | -99% |
Profit Growth | - | - | 0.690 | 0.690 | 0% | -0.212 | +131% | 0.103 | +571% | 1.709 | -60% |
Quick Ratio | - | - | 0.598 | 0.598 | 0% | 1.264 | -53% | 1.397 | -57% | 1.271 | -53% |
Return On Assets | - | - | -0.213 | -0.213 | 0% | -0.143 | -33% | -0.131 | -39% | -0.050 | -76% |
Return On Equity | - | - | -0.485 | -0.485 | 0% | -0.272 | -44% | -0.248 | -49% | -0.093 | -81% |
Revenue Growth | - | - | 1.059 | 1.059 | 0% | 0.877 | +21% | 0.945 | +12% | 1.310 | -19% |
Total Gains Per Share | - | - | 6.058 | 6.058 | 0% | -0.191 | +103% | 1.130 | +436% | 0.641 | +846% |
Total Gains Per Share Growth | - | - | 33.794 | 33.794 | 0% | -29.984 | +189% | 0.945 | +3476% | 5.505 | +514% |
Usd Book Value | - | - | 367810624.000 | 367810624.000 | 0% | 509396455.800 | -28% | 610057017.760 | -40% | 456280989.080 | -19% |
Usd Book Value Change Per Share | - | - | 3.999 | 3.999 | 0% | -0.126 | +103% | 0.746 | +436% | 0.423 | +846% |
Usd Book Value Per Share | - | - | 4.323 | 4.323 | 0% | 0.324 | +1234% | 1.222 | +254% | 0.765 | +465% |
Usd Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Usd Eps | - | - | -2.044 | -2.044 | 0% | -0.088 | -96% | -0.471 | -77% | -0.226 | -89% |
Usd Free Cash Flow | - | - | -7825350.600 | -7825350.600 | 0% | -16569039.400 | +112% | -18330717.080 | +134% | -87931179.740 | +1024% |
Usd Free Cash Flow Per Share | - | - | -0.092 | -0.092 | 0% | -0.011 | -89% | -0.029 | -68% | -0.074 | -20% |
Usd Free Cash Flow To Equity Per Share | - | - | 0.122 | 0.122 | 0% | -0.028 | +123% | 0.011 | +1031% | 0.030 | +302% |
Usd Price Per Share | 2.502 | +93% | 0.165 | 0.165 | 0% | 0.211 | -22% | 0.308 | -46% | 0.491 | -66% |
Usd Profit | - | - | -180861790.000 | -180861790.000 | 0% | -138035936.400 | -24% | -131419676.080 | -27% | -55666347.480 | -69% |
Usd Revenue | - | - | 279868683.000 | 279868683.000 | 0% | 264291924.200 | +6% | 308172909.440 | -9% | 233488312.600 | +20% |
Usd Total Gains Per Share | - | - | 3.999 | 3.999 | 0% | -0.126 | +103% | 0.746 | +436% | 0.423 | +846% |
EOD | +3 -2 | MRQ | TTM | +0 -0 | YOY | +21 -19 | 5Y | +19 -21 | 10Y | +19 -21 |
4.2. Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | -1.224 | |
Price to Book Ratio (EOD) | Between | 0-1 | 0.579 | |
Net Profit Margin (MRQ) | Greater than | 0 | -0.646 | |
Operating Margin (MRQ) | Greater than | 0 | 0.027 | |
Quick Ratio (MRQ) | Greater than | 1 | 0.598 | |
Current Ratio (MRQ) | Greater than | 1 | 0.838 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 0.567 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 1.294 | |
Return on Equity (MRQ) | Greater than | 0.15 | -0.485 | |
Return on Assets (MRQ) | Greater than | 0.05 | -0.213 | |
Total | 3/10 (30.0%) |
4.3. Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Rsi | Greater than | 50 | 50.435 | |
Ma 20 | Greater than | Ma 50 | 3.728 | |
Ma 50 | Greater than | Ma 100 | 3.864 | |
Ma 100 | Greater than | Ma 200 | 3.647 | |
Open | Greater than | Close | 3.900 | |
Total | 3/5 (60.0%) |
Reversals in quarterly reports
I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.
2018-06-30 | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Net Working Capital | 300,870 | -40,253 | 260,617 | 11,077 | 271,694 | -77,693 | 194,001 | -292,804 | -98,803 | |
Tax Provision | -41,199 | -33,644 | -74,843 | 35,698 | -39,145 | -15,660 | -54,805 | 110,937 | 56,132 | |
Income Tax Expense | -32,530 | -37,436 | -69,966 | 29,134 | -40,832 | -13,973 | -54,805 | 110,937 | 56,132 |
Latest Balance Sheet
Balance Sheet of 2022-06-30. Currency in AUD. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 730,806 |
Total Stockholder Equity | + 564,773 |
Total Assets | = 1,287,926 |
Assets
Total Current Assets
Long-term Assets
Property Plant Equipment | 225,855 |
Goodwill | 22,127 |
Intangible Assets | 405,387 |
Long-term Assets Other | 4,450 |
Long-term Assets (as reported) | 776,308 |
---|---|
Long-term Assets (calculated) | 657,819 |
+/- | 118,489 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Total Stockholder Equity
Common Stock | 1,238,537 |
Retained Earnings | -822,406 |
Other Stockholders Equity | 148,642 |
Total Stockholder Equity (as reported) | 564,773 |
---|---|
Total Stockholder Equity (calculated) | 564,773 |
+/- | 0 |
Balance Sheet
Currency in AUD. All numbers in thousands.
Trend | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 | 2018-06-30 | 2017-06-30 | 2016-06-30 | 2015-06-30 | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 | 2009-06-30 | 2008-06-30 | 2007-06-30 | 2006-06-30 | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 1,287,926 | 1,463,184 | 1,825,180 | 1,636,333 | 1,830,507 | 1,914,920 | 1,557,381 | 528,946 | 265,820 | 233,391 | 53,933 | 53,677 | 71,149 | 8,036 | 11,693 | 15,510 | 29 | |||||||||||||||||
> Total Current Assets |
| 511,618 | 416,528 | 490,947 | 471,946 | 480,767 | 429,003 | 1,108,650 | 156,820 | 65,895 | 61,909 | 23,255 | 18,838 | 32,529 | 8,013 | 11,648 | 15,453 | 0 | |||||||||||||||||
Cash And Cash Equivalents |
| 96,672 | 97,980 | 137,785 | 89,004 | 87,312 | 63,027 | 47,481 | 59,201 | 14,813 | 18,938 | 11,596 | 5,807 | 19,709 | 7,936 | 11,531 | 15,303 | 29 | |||||||||||||||||
Short-term Investments |
| 0 | 0 | 0 | 563 | 6,747 | 6,208 | 3,458 | 2,229 | 1,172 | 1,825 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||
Net Receivables |
| 268,241 | 183,283 | 195,908 | 256,580 | 252,715 | 232,716 | 123,716 | 64,657 | 29,805 | 24,622 | 3,821 | 5,697 | 5,999 | 39 | 47 | 80 | 0 | |||||||||||||||||
Other Current Assets |
| 37,797 | 32,755 | 63,257 | 26,014 | 51,837 | 20,658 | 895,052 | 8,289 | 2,869 | 2,931 | 594 | 911 | 321 | 37 | 70 | 70 | 0 | |||||||||||||||||
> Long-term Assets |
| 776,308 | 1,046,656 | 1,334,233 | 1,164,387 | 1,349,740 | 1,485,917 | 448,731 | 372,126 | 199,925 | 171,482 | 30,678 | 34,839 | 38,621 | 23 | 45 | 57 | 0 | |||||||||||||||||
Property Plant Equipment |
| 225,855 | 221,595 | 238,244 | 236,034 | 230,051 | 189,272 | 84,449 | 59,597 | 53,409 | 55,036 | 22,224 | 21,457 | 21,047 | 23 | 45 | 57 | 0 | |||||||||||||||||
Goodwill |
| 22,127 | 20,346 | 22,174 | 21,725 | 20,616 | 58,217 | 60,115 | 58,436 | 47,476 | 47,197 | 391 | 391 | 391 | 0 | 0 | 0 | 0 | |||||||||||||||||
Long Term Investments |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,076 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||
Intangible Assets |
| 405,387 | 615,808 | 940,117 | 775,907 | 1,033,910 | 1,177,224 | 272,368 | 244,524 | 93,639 | 68,273 | 3,803 | 7,792 | 13,835 | 0 | 0 | 0 | 0 | |||||||||||||||||
Other Assets |
| -606,224 | -302,376 | 174,398 | 183,499 | 167,389 | 152,815 | 31,799 | 9,569 | 34,763 | 18,981 | 4,260 | 5,199 | 3,347 | 0 | 0 | 0 | 0 | |||||||||||||||||
> Total Liabilities |
| 730,806 | 691,605 | 782,867 | 622,258 | 595,350 | 602,496 | 1,181,160 | 206,744 | 106,546 | 112,502 | 23,333 | 29,503 | 45,600 | 332 | 255 | 996 | 7 | |||||||||||||||||
> Total Current Liabilities |
| 610,421 | 222,527 | 219,253 | 211,329 | 179,897 | 199,895 | 1,055,924 | 95,078 | 30,379 | 42,111 | 12,304 | 14,939 | 23,167 | 318 | 253 | 991 | 7 | |||||||||||||||||
Short-term Debt |
| 407,993 | 54,043 | 44,836 | 50,881 | 58 | 13,124 | 503 | 2,229 | 2,374 | 7,471 | 0 | 2,339 | 7,587 | 2 | 3 | 3 | 0 | |||||||||||||||||
Short Long Term Debt |
| 405,367 | 51,158 | 44,836 | 50,861 | 374,190 | 13,011 | 76,834 | 61,756 | 48,030 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||
Accounts payable |
| 63,571 | 42,363 | 29,842 | 50,443 | 63,888 | 66,593 | 135,508 | 51,572 | 7,131 | 6,832 | 2,893 | 2,142 | 2,227 | 119 | 135 | 166 | 7 | |||||||||||||||||
Other Current Liabilities |
| 138,857 | 126,121 | 144,575 | 110,005 | 115,951 | 120,178 | 919,913 | 43,506 | 20,874 | 27,808 | 9,411 | 10,458 | 13,353 | 197 | 115 | 821 | 0 | |||||||||||||||||
> Long-term Liabilities |
| 120,385 | 469,078 | 563,614 | 410,929 | 415,453 | 402,601 | 125,236 | 111,666 | 76,167 | 70,391 | 11,029 | 14,564 | 22,433 | 14 | 2 | 6 | 0 | |||||||||||||||||
Long term Debt Total |
| 5,673 | 292,776 | 353,211 | 318,501 | 374,132 | 327,122 | 76,331 | 62,754 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||
Other Liabilities |
| 114,712 | 176,302 | 210,403 | 92,430 | 40,494 | 75,479 | 48,905 | 49,910 | 8,726 | 10,594 | 7,299 | 10,086 | 15,856 | 14 | 2 | 6 | 0 | |||||||||||||||||
Deferred Long Term Liability |
| -729,163 | -491,283 | 40,700 | 53,373 | 102,225 | 91,611 | 72,048 | 51,562 | 33,438 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||
> Total Stockholder Equity |
| 564,773 | 768,357 | 1,037,547 | 1,007,766 | 1,226,464 | 1,303,838 | 363,749 | 310,870 | 159,274 | 120,889 | 30,600 | 24,174 | 25,550 | 7,704 | 11,438 | 14,514 | 21 | |||||||||||||||||
Common Stock |
| 1,238,537 | 1,238,537 | 1,238,584 | 1,140,008 | 1,131,761 | 1,130,404 | 263,161 | 255,834 | 137,498 | 118,302 | 32,016 | 31,870 | 29,649 | 15,869 | 15,869 | 15,908 | 30 | |||||||||||||||||
Retained Earnings Total Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||
Accumulated Other Comprehensive Income |
| 148,642 | 88,883 | 149,603 | 125,099 | 71,178 | 23,337 | 39,058 | 30,861 | 5,360 | 7,461 | 1,087 | 960 | 1,714 | 902 | 875 | 439 | 0 | |||||||||||||||||
Capital Surplus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||
Other Stockholders Equity |
| 148,642 | 88,883 | 149,603 | 125,011 | 71,178 | 23,337 | 29,928 | 27,631 | 5,360 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Balance Sheet
Currency in AUD. All numbers in thousands.
Cash Flow
Currency in AUD. All numbers in thousands.
Income Statement
Currency in AUD. All numbers in thousands.
Latest Income Statement (annual, 2022-06-30)
Gross Profit (+$) | ||
---|---|---|
totalRevenue | 423,915 | |
Cost of Revenue | -253,769 | |
Gross Profit | 170,146 | 170,146 |
Operating Income (+$) | ||
Gross Profit | 170,146 | |
Operating Expense | -171,691 | |
Operating Income | 11,316 | -1,545 |
Operating Expense (+$) | ||
Research Development | 14,661 | |
Selling General Administrative | 28,651 | |
Selling And Marketing Expenses | 104,600 | |
Operating Expense | 171,691 | 147,912 |
Net Interest Income (+$) | ||
Interest Income | 461 | |
Interest Expense | -32,098 | |
Other Finance Cost | -331 | |
Net Interest Income | -31,968 | |
Pretax Income (+$) | ||
Operating Income | 11,316 | |
Net Interest Income | -31,968 | |
Other Non-Operating Income Expenses | - | |
Income Before Tax (EBT) | -217,818 | 240,450 EBIT - interestExpense = -20,782 -217,818 -241,852 |
Interest Expense | 32,098 | |
Earnings Before Interest and Taxes (EBIT) | 11,316 | -185,720 |
Earnings Before Interest and Taxes (EBITDA) | 92,397 | |
After tax Income (+$) | ||
Income Before Tax | -217,818 | |
Tax Provision | -56,132 | |
Net Income From Continuing Ops | -273,950 | -273,950 |
Net Income | -273,950 | |
Net Income Applicable To Common Shares | -263,343 | |
Non-recurring Events | ||
Discontinued Operations | - | |
Extraordinary Items | -492 | |
Effect of Accounting Charges | - | |
Other Items | - | |
Non Recurring | - | |
Other Operating Expenses | 425,460 | |
Total Other Income/Expenses Net | -229,134 | 31,968 |
Technicals of Mayne Pharma Group Ltd
1. Trend Indicators
1.1 Moving Averages
- Moving averages are lagging trend indicators.
- There are many types of moving averages.
- Moving averages are also used within other indicators.
Directionalities and relatives.
Moving Average | Amount of candles | Trend | Price +/- | vs. MA 50 | vs. MA 100 | vs. MA 200 |
---|---|---|---|---|---|---|
MA 20 | 20 | |||||
MA 50 | 50 | - | ||||
MA 100 | 100 | - | - | |||
MA 200 | 200 | - | - | - |
Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I